Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify
Propelled by a flurry of dealmaking late in the year, M&As in 2025 ended on a strong note, with high activity expected to continue in 2026.
UK slashes 2026 drug rebate rate by one-third to win back pharma sentiments
Pfizer plans job cuts in Switzerland to reduce expenses
Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility
Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor
Crenolanib delivers incremental benefit in FLT3/NPM1 co-mutated AML
Analysis
View More
Themes
View MoreEli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
The partnership is the latest in a long line of AI-centric projects in drug discovery and development.
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?
Trump blames Covid-19 drugmakers for fuelling CDC turmoil